To learn more about our prospective biomarker study please click here.
Idylla™ ctEGFR Available Now! Click here for more information

November 7 - 9, 2019 | Baltimore Convention Center

AMP 2019 Annual Meeting

The AMP Annual Meeting has truly become pathology’s global event. Decision makers in the field of pathology and the related specialties of molecular, toxicology, oncology, and immunology from hospitals, private laboratories, academic institutions, and the government will be in attendance. We are continually setting records for attendance and the number of exhibitors over the past several years and look forward to doing the same in 2019.


November 7 - 9, 2019
Baltimore Convention Center
Booth #2840

Join our corporate workshop on Wednesday, November 6! Learn more about Biocartis’ fully-automated oncology biomarker testing platform from three experienced Idylla™ users:

High sensitivity mutation analysis in pleural and pancreatic fluids
Dr. Maria Arcila,
Memorial Sloan Kettering Cancer Center

A multicenter study of improved TAT for somatic mutation analysis
Dr. Gregory J. Tsongalis,
Dartmouth-Hitchcock Medical Center

Implementation and cost benefit analysis of the fully automated Idylla™ system in a large laboratory setting
Dr. Yi Ding,
Geisinger Medical Laboratories

Request A Demo

Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.

One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.